semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancers Diagnosis of cancer with evidence of active disease 2. Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average intensity level >/=3/10 on the numeric rating scale 3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology or Cardiopulmonary Center 4. Ambulatory and able to walk with or without walking aid 5. On strong opioids with morphine equivalent daily dose of 60-130 mg for at least one week, with stable (i.e. +/ ) regular dose over the last 24 hours 6. Karnofsky performance status >/=50% 7. Age 18 or older 8. Able to complete study assessments 9. Must speak and understand English  Dyspnea at rest >/=7/10 at the time of enrollment 2. Supplemental oxygen requirement >6 L per minute 3. Delirium (i.e. Memorial delirium rating scale >13) 4. History of unstable angina or myocardial infarction 1 month prior to study enrollment 5. Resting heart rate >120 at the time of study enrollment 6. Systolic pressure >180 mmHg or diastolic pressure >100 mmHg at the time of study enrollment 7. History of active opioid abuse within the past 12 months 8. History of allergy to fentanyl 9. Severe anemia (Hb <7g/L) if documented in the last month and not corrected prior to study enrollment* 10. Bilirubin >5X Upper limit of normal if documented in the last month and not lowered to <5x normal prior to study enrollment* 11. Diagnosis of acute pulmonary embolism within past 2 weeks 12. Diagnosis of pulmonary hypertension 13. Unwilling to provide informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Congestive Heart Failure Low Cardiac Output hospitalization for decompensated heart failure dobutamine dependence ejection fraction < 0.45 taking angiotensin-converting enzyme inhibitor  serum creatinine > 3.0 mg/dL serum potassium > 6.0 mEq/L systolic blood pressure < 70 mm Hg aortic stenosis acute coronary syndrome in the previous 2 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Subjects will be healthy male subjects, who are considered to be generally healthy based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator Body mass index (BMI) between 18.0-27.0 kg/m^2 (both inclusive) WITH TYPE 1 AND TYPE 2 Subjects will be male volunteers, who are considered to be generally healthy, except for the underlying diabetes mellitus, based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months or diagnosed with type 2 diabetes mellitus for at least 12 months Body Mass Index (BMI) between 18.0-27.0 kg/m^2 (both inclusive) for subjects with type 1 diabetes or 25.0-35.0 kg/m^2 (both inclusive) for subjects with type 2 diabetes Glycogylated haemoglobin (HbA1c) maximum 8.5 % based on central laboratory results Subjects with type 2 diabetes must have been treated with insulin for the past 3 months prior to screening  Participation in any other trials involving investigational products within 3 months preceding the start of dosing History of significant multiple drug allergies or with a known allergy to the trial product or any medicine chemically related to the trial product, as judged by the investigator Hepatitis or carrier of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies or a positive result to the test for human immunodeficiency (HIV) antibodies Any clinically significant abnormal haematology or biochemistry screening tests, as judged by the investigator Subjects who have donated any blood or plasma in the past month or in excess of 1000 ml within the 12 weeks preceding screening
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-69.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Glycosylated haemoglobin (HbA1c) below or equal to 10 procent based on central laboratory results Specific for subject with type 1 diabetes Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months prior to screening Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive) Specific for subject with type 2 diabetes Diagnosed with type 2 diabetes mellitus for at least 12 months prior to screening Treated with insulin for the past 3 months prior to screening Body Mass Index (BMI) between 22.0 and 35.0 kg/ m^2 (both inclusive)  Subject with a history of significant multiple drug allergies or with a known allergy or suspected allergy to the trial product or any medicine chemically related to the trial product,as judged by the Investigator Subject with a history of or presence of cancer Any condition that the Investigator and/or Sponsor feels would interfere with study Specific for subject with type 2 diabetes Therapy with oral antidiabetic drugs within the past 3 months prior to screening
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Heart Failure Patients over 18 years of age with chronic heart failure, ischemic and non-ischemic etiology NYHA (New York Heart Association) class II-IV LVEF (Left Ventricular Ejection Fraction) ≤ 35% Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure, who were stable for at least four weeks without acute decompensated heart failure Prior to enrollment, patients must give informed consent  Patients with history of acute coronary syndrome or stroke within the last 6 months Significant valvular defects and/or planned cardiac surgery Systolic blood pressure <110 mmHg Advanced renal insufficiency (estimated GFR (Glomerular Filtration Rate) according to MDRD <30 ml/min/1.73 square meters) Unsuitable anatomy of renal arteries (presence of significant renal stenosis, renal artery narrower than 4 mm) Patients who underwent renal angioplasty or stent placement into the renal artery in the past Severe coagulation disorders Pregnancy or lactation Refusal of the patient Other diseases limiting prognosis of the patient to less than 2 years
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Type 2 Diabetes Coronary Artery Disease Left Ventricular Mass Type 2 diabetes CAD Left ventricular hypertrophy HbA1c below 7.0% blood pressure <130/80 mmHg  Patients were excluded if they were currently alpha-lipoic acid for one year, had a previous adverse reaction to alpha-lipoic acid hey were also excluded if they had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 45.0-65.0,  Hypercholesterolemia between 45-65 years old mildly hypercholesterolemic (total cholesterol levels between 4.9 and 6.7 mmol/L, 190 and 260 mg/dl) high-density lipoprotein cholesterol (HDL-C) between 0.9 and 1.6 mmol/L (35 and 65 mg/dl) triglyceride (TG) concentrations below 6.8 mmol/L (600 mg/dl) habitually consumed a typical American diet with low dietary flavonoid intake (<4 one-half cup servings of fruits and vegetables/day) and low intake (<1 serving/day) of soy-rich foods, nuts, herbs, and spices (besides salt and pepper) aspartate aminotransferase (AST) between 0 and 55 mg/L creatinine between 70.7 and 150.3 mmol/L (0.8 and 1.7 mg/dl) glucose between 3.3 and 6.4 mmol/L (60 and 115 mg/dl)  current smoker usage of high amounts of antioxidant vitamin supplements (>3 times the Recommended Dietary Allowance (RDA) of vitamins E, C, and selenium, or >10 mg/day of beta carotene) had been diagnosed with diabetes, coagulation disorders, chronic pulmonary disease, current active malignancy, renal disease requiring dialysis, malabsorption, or gastrointestinal disorders, or had a history of cardiovascular disease antihypertensive, immunosuppressive, cholesterol lowering, or anticoagulant medications consuming >3 servings of alcohol daily Pre-menopausal (women)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes men and women ≥ 18 years of age patients with type 1 diabetes for more than 2 years patients treated by insulin pump for more than 6 months patients using of real-time continuous glucose monitoring for more than 3 months patients able to evaluate the IPRA advices by connecting to IPRA© application 30 times a week patient able to provide written informed consent patient able to provide written non-disclosure agreement  pregnancy or breastfeeding current infectious disease patients with no smartphone® or Internet access adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Chronic Heart Failure adults age 19 or older who have Class III through IV heart failure as classified by the New York Heart Association (NYHA) cognitively intact indicated by being able to describe what participation in the study will involve have a consistent informal caregiver, who is willing to provide support to the participants, and a telephone residing in a rural area (population less than 2,500) (U.S. Census, 1995)  myocardial infarction or coronary bypass surgery within the last three months active chest pain uncontrolled arrhythmia (atrial fibrillation or ventricular tachycardia) on transplant list or has ventricular assist device skeletal or neurological conditions that would impact muscle strength or interfere with 6 minute walk test (6MWT) (amputation, severe arthritis, Parkinson's, stroke, or severe neuropathy) history of severe COPD
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 22.0-999.0,  Type 1 Diabetes Mellitus Patients with T1D lasted >1 year, age 22 and up, using insulin pump Patients possessing a mobile phone and internet access  Patients with Severe target organ damage Patients with Mental retardation Patients with Eating disorders Pregnant patients or patients planning pregnancy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Registered at the National List of persons taking part in clinical research Signed consent form Subjects of both genders aged of at least 18 years Perfect understanding of the instructions and of sensory scaling Prior medical examination  Any current or past disease, in particular respiratory, neurological and psychiatric disorders Regular use of drugs, especially those having an impact on respiratory, neurological systems (most specifically those with an effect on the central nervous system) Unwilling to participate Vulnerable people as defined in the provisions relating to biomedical researches and described in the Code of Public Health Unable to cooperate Pregnancy or lactation No affiliation to a social security system
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carnitine Deficiency An adult patient (>18 years) with a diagnosis of either hypertrophic or dilated cardiomyopathy, for which the underlying etiology of the cardiomyopathy is unknown  A history of ischemia A documented or suspected infection including HIV A history of severe longstanding hypertension A history of valvular heart disease A history of chemotherapy exposure A history of alcohol abuse Carnitine supplementation at the time of recruitment
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Diabetes Mellitus, Type 2 subjects aged more than 30 years no history of chronic diseases no use of blood glucose lowering drugs be wiling to participate to study  do not follow study protocol incidence of chronic diseases during the study to start use of blood glucose lowering drugs or to change dose and type of current medications
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-69.0,  Dyslipidemia Hypercholesterolemia Hypertriglyceridemia Between 18 and 69 years at Screening Hypertriglyceridemia (TG ≥ 200 mg/dL and < 500 mg/dL and non-HDL-C ≥ 100 mg/dL and < 220 mg/dL) OR Hypercholesterolemia (LDL-C ≥ 100 mg/dL and < 190 mg/dL and TG value < 200 mg/dL) plus a stable dose of statin for at least 4 weeks prior to Screening Body mass index (BMI) ≤ 45 kg/m2  History of any major cardiovascular event within 6 months of Screening Type I diabetes mellitus Any condition that may predispose the patient to secondary hyperlipidemia, such as uncontrolled hypothyroidism Any statin at the highest approved dose Non-statin lipid-altering drugs other than cholesterol absorption inhibitors Active peptic ulcer disease or a history of muscle disease or myopathy